Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy Academic Article uri icon

Overview

MeSH Major

  • Anemia, Sickle Cell
  • Blood Transfusion
  • Chelation Therapy
  • Deferoxamine
  • Iron
  • Pulmonary Embolism

abstract

  • Pulmonary disease, including thromboembolic problems, accounts for a large portion of the morbidity of sickle cell disease. Chronic transfusion therapy is now a part of long-term treatment of sickle cell patients with stroke and chest syndrome. The resultant iron overload must be treated with chelation therapy using deferoxamine. Poor compliance with subcutaneous chelation therapy has necessitated intravenous deferoxamine treatment. We describe two patients with sickle cell disease on such a regimen, who became hypoxic as a result of pulmonary thromboembolism, secondary to venous thrombophlebitis. The thrombophlebitis and subsequent pulmonary embolism probably reflect the hypercoagulable state seen in sickle cell and are not due to the deferoxamine therapy.

publication date

  • December 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s002470050273

PubMed ID

  • 9388284

Additional Document Info

start page

  • 926

end page

  • 8

volume

  • 27

number

  • 12